Last reviewed · How we verify

NCT06334406: immunoBLAD

Antitumor T Cell Responses in Patients With Bladder Cancer

Status unknown Last updated 28 March 2024
What this trial tests

trial testing Biological samples in Bladder Cancer in 33 participants. Status unknown.

Timeline
2 April 2024
Primary endpoint
2 April 2026
2 April 2026

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Besancon
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment33
Start date2 April 2024
Primary completion2 April 2026
Estimated completion2 April 2026

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatments in patients with bladder tumor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Biological samples

Trials testing the same drug.

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06334406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing